Show simple item record

dc.contributor.authorDobson, R
dc.contributor.authorFenton, N
dc.contributor.authorHartmann, M
dc.date.accessioned2021-04-12T13:35:56Z
dc.date.available2021-03-10
dc.date.available2021-04-12T13:35:56Z
dc.date.issued2021-03
dc.identifier.citationHartmann, Morghan et al. "Current Review And Next Steps For Artificial Intelligence In Multiple Sclerosis Risk Research". Computers In Biology And Medicine, vol 132, 2021, p. 104337. Elsevier BV, doi:10.1016/j.compbiomed.2021.104337. Accessed 12 Apr 2021.en_US
dc.identifier.issn0010-4825
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/71187
dc.description.abstractIn the last few decades, the prevalence of multiple sclerosis (MS), a chronic inflammatory disease of the nervous system, has increased, particularly in Northern European countries, the United States, and United Kingdom. The promise of artificial intelligence (AI) and machine learning (ML) as tools to address problems in MS research has attracted increasing interest in these methods. Bayesian networks offer a clear advantage since they can integrate data and causal knowledge allowing for visualizing interactions between dependent variables and potential confounding factors. A review of AI/ML research methods applied to MS found 216 papers using terms “Multiple Sclerosis”, “machine learning”, “artificial intelligence”, “Bayes”, and “Bayesian”, of which 90 were relevant and recently published. More than half of these involve the detection and segmentation of MS lesions for quantitative analysis; however clinical and lifestyle risk factor assessment and prediction have largely been ignored. Of those that address risk factors, most provide only association studies for some factors and often fail to include the potential impact of confounding factors and bias (especially where these have causal explanations) that could affect data interpretation, such as reporting quality and medical care access in various countries. To address these gaps in the literature, we propose a causal Bayesian network approach to assessing risk factors for MS, which can address deficiencies in current epidemiological methods of producing risk measurements and makes better use of observational data.en_US
dc.publisherElsevieren_US
dc.relation.ispartofComputers in Biology and Medicine
dc.rightshttps://doi.org/10.1016/j.compbiomed.2021.104337
dc.titleCurrent Review and Next Steps for Artificial intelligence in Multiple Sclerosis risk researchen_US
dc.typeArticleen_US
dc.rights.holder© 2021 Elsevier Ltd.
pubs.notesNot knownen_US
pubs.publication-statusAccepteden_US
dcterms.dateAccepted2021-03-10
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record